KALA BIO, Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company building a dedicated AI infrastructure platform for the biotechnology industry, has implemented a 1-for-50 reverse stock split of its common stock. The reverse split became effective at 4:05 p.m. on May 8, 2026, with split-adjusted trading set to begin on the Nasdaq Capital Market at the open on May 11, 2026. The move reduces the company's outstanding common shares from approximately 929.5 million to 18.6 million.
Under the reverse split, cash payments will be issued in lieu of fractional shares, and proportional adjustments will be made to outstanding equity awards, warrants and other convertible securities. The action is likely aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement and improve the company's marketability to institutional investors.
KALA BIO is not a traditional biopharmaceutical firm. The company describes itself as building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. Its dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business. This AI platform is designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.
Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The company's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.
The reverse stock split comes as KALA seeks to strengthen its financial position and continue its strategic pivot toward AI-driven solutions for biotech. For investors and industry observers, the move signals a commitment to maintaining Nasdaq listing and potentially attracting new capital. The reduction in share count could also lead to a higher stock price, which may appeal to institutional investors who avoid low-priced stocks.
For the broader biotech and AI industries, KALA's strategy represents a convergence of two high-growth sectors. The company's AI platform-as-a-service model addresses a critical need for secure, on-premises AI infrastructure that allows biotech firms to leverage proprietary data without compromising control. As AI adoption accelerates in life sciences, KALA's platform could become a key enabler for drug discovery and development.
More details on the reverse split and KALA's business strategy are available in the full press release at InvestorWire. Additional information about the company can be found on its website at Researgency.ai.
